Introduction
With the increasing prevalence of diabetes mellitus, there is a need for anaesthetists to be aware of developments in oral hypoglycaemic drugs. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, a relatively new class of oral hypoglycaemics, are prescribed for type-2 diabetes mellitus as second-line therapy, often in combination with other oral hypoglycaemics or insulin. The SGLT2 inhibitors available include empagliflozin and dapagliflozin, canagliflozin, ipragliflozin, tofogliflozin and luseogliflozin. They inhibit renal glucose re-absorption, promoting glycosuria [1] with relatively few adverse effects. As their mode of action is independent of pancreatic b cell function, they are increasingly being prescribed off label to type-1 diabetic (T1DM) patients. Of concern to anaesthetists is their propensity to cause 'euglycaemic' ketoacidosis in the peri-operative period.
The aim of this article is to provide a critical appraisal of the pharmacology and safety profile of the SGLT2 inhibitors, and to increase the awareness of peri-operative physicians to SGLT2 inhibitor-associated 'euglycaemic' diabetic ketoacidosis. controlled trials, case reports and reviews. We then manually searched the reference lists for additional case reports specifically related to peri-operative diabetic ketoacidosis, resulting in a total of 62 articles.
Pharmacology
The re-absorption of glucose is coupled with sodium via carrier proteins in the apical cell membrane of the proximal tubule, called sodium-glucose co-transporters (SGLTs). The maximum amount of glucose that can be re-absorbed (T max ) is about 375 mg.min À1 [2] .
Sodium-glucose co-transporter 2 is specifically expressed in the S1 segment of the proximal convoluted tubule of the kidney and is responsible for approximately 97% of glucose re-absorption [2] [3] [4] . Sodiumglucose co-transporter 1 is primarily expressed in the small intestine but is also found in the more distal portion of the proximal convoluted tubule (S2/S3 segment), as well as the lung and liver [1, 3] . Minimal glucose is present in the urine until the plasma glucose concentration increases above about 11 mmol.L -1 . In patients with type-2 diabetes, SGLT2 is upregulated in the proximal convoluted tubule, resulting in increased glucose re-absorption, exacerbating hyperglycaemia and insulin resistance [5, 6] . Sodium-glucose co-transporter 2 inhibitors reduce T max and this results in glycosuria. Approximately 50-100 g.day -1 of glucose (approximately 30% of daily carbohydrate intake) is lost in the urine with complete SGLT2 inhibition [7] . The mean reduction in HbA1c associated with SGLT2 inhibitors range from approximately 0.5% to 1% [8] .
The risk of hypoglycaemia is low because SGLT2 inhibitors cause less glycosuria as the plasma glucose level declines. There is an upregulation of SGLT1 in response to SGLT2 inhibition, attenuating the degree of glycosuria [4] . Urinary glucose excretion results in caloric loss, translating into weight loss of approximately 2-3 kg [5] . As a consequence of decreased sodium re-absorption and the osmotic diuretic effects of glucose in the renal tubules, SGLT2 inhibitors cause a 5%-10% reduction in extracellular volume [9] . SGLT2 inhibitors reduce both systolic and diastolic blood pressure without causing a compensatory tachycardia, suggesting they may also reduce underlying sympathetic tone [1, 5] . Cardiovascular mortality caused by insulin resistance and associated metabolic abnormalities accounts for approximately 80% of the increased mortality risk of a type-2 diabetic (T2DM) patient [5] . Traditional hypoglycaemic therapy has failed to demonstrate a significant reduction in cardiovascular mortality [10] [11] [12] [13] . A recent trial demonstrated a significant reduction in cardiovascular mortality in a cohort of high-risk T2DM patients taking empagliflozin [14] . In this study of > 7000 T2DM patients, empagliflozin reduced the risk of cardiovascular death by 38% (p = 0.001), but did not cause a significant reduction in the incidence of non-fatal myocardial infarction or stroke. Furthermore, it was associated with a reduction in hospitalisation for congestive cardiac failure [14] .
Tubular 'hyper-reabsorption' secondary to SGLT2 upregulation is postulated to induce glomerular hyperfiltration (via tubuloglomerular feedback), thereby worsening diabetic nephropathy [4] . Empagliflozin reduces glomerular hyperfiltration and effective renal plasma flow in T1DM patients [15] . In T2DM diabetic patients with chronic renal impairment, empagliflozin and canagliflozin are associated with moderate reductions in GFR [16, 17] . This may be renal protective in the long term by protecting against the deleterious effects of tubular hyperfiltration [4] . The SGLT2 inhibitors increase the risk of genital and urinary tract infections, particularly with fungal organisms, as a result of the glycosuria [1] .
Of the SGLT2 inhibitors available, canagliflozin has the least selectivity for SGLT2 receptor and has some SGLT1 inhibitory effects. Consistent with this, canagliflozin has been shown to delay intestinal glucose absorption [18] . SGLT1, expressed in the apical membrane of the small bowel epithelium, mediates glucose and galactose re-absorption. It is also expressed on L and K cells in the small bowel and colon, which secrete the incretins glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) [4] . Increased delivery of glucose to the colon has been postulated to stimulate the secretion of incretins, resulting in increased insulin release and reduced glucagon secretion [19] .
The relevant pharmacokinetic data of the SGLT2 inhibitors is summarised in Table 1 .
Euglycaemic ketoacidosis
Of concern to the anaesthetist is the association between SGLT2 inhibitors and diabetic ketoacidosis in the peri-operative period, which may occur with normal or moderately increased blood sugar levels. This has been termed euglycaemic ketoacidosis, and is said to occur when the plasma glucose level is less than 14 mmol.L -1 [20] . The American Association of Clinical Endocrinologists and the American College of Endocrinology advise against using the word 'euglycaemic' as the plasma glucose is still often higher than normal values, and instead suggest the term 'DKA with lower-than-anticipated glucose levels' [21] . Regardless of semantics, the concern is that anaesthetists, surgeons and peri-operative physicians will miss the diagnosis of ketoacidosis because the plasma glucose level is not particularly high. In 2015, the Food and Drug Administration cautioned that SGLT2 inhibitors may increase the risk of ketoacidosis based on 20 cases [21] . The European Medicines Agency subsequently reported 147 cases of ketoacidosis associated with SGLT2 inhibitors [22] . The type-2 diabetes clinical trials for canagliflozin, dapagliflozin and empagliflozin have accumulated 44,000 patient years of exposure to SGLT2 inhibitors with diabetic ketoacidosis incidence rates varying from 0.16 to 0.76 event per 1000 patient years [23, 24] . The absolute risk was still relatively low (0.8 and 0.2 per 1000 patient years with canagliflozin 100 and 300 mg, respectively) [23] . The lowest event rate of ketoacidosis occurred with dapagliflozin: 0.16 per 1000 patient years [20] . Based on pooled clinical trial data of empagliflozin, Lund et al. reported event rates between 0.2 and 0.6 per 1000 patient years [24] . Tang et al. conducted a meta-analysis that included 13,134 patients from 10 randomised controlled trials that recorded 14 events of diabetic ketoacidosis, indicating that the SGLT2 inhibitor arm (11 events, 0.1%) did not show a significantly higher risk of diabetic ketoacidosis compared with the control groups (three events, 0.06%) with an odds ratio of 1.71 (CI, 0.56-5.2) [25] . This finding was replicated in another recently published meta-analysis [26] .
However, the risk of ketoacidosis appears higher when analysing data not sourced from clinical trials, which perhaps is more representative of an inpatient cohort. Using an insurance claims database, Fralick et al. calculated the hazard ratios of developing diabetic ketoacidosis in patients prescribed SGLT2 inhibitors compared with dipeptidyl peptidase-4 inhibitors (DPP4) (50,220 patients were prescribed an SGLT2 inhibitor) [27] . Using propensity-score matching, the hazard ratio was 2.2 (95%CI 1.4-3.6), with an event rate of 4.9 per 1000 patient years in the SGLT2 group compared with 2.2 in the DPP4 group [27] . Using the FDA Adverse Event Reporting System (FAERS) database, Blau et al. reported a sevenfold increased risk of ketoacidosis in T2DM patients taking SGLT2 inhibitors compared with DPP4 inhibitors [28] . Seventy-one per cent of cases had euglycaemic ketoacidosis [28] . Using the same FAERS database, Fadini et al. identified 2589 reports of diabetic ketoacidosis where an SGLT2 inhibitor was listed as a suspect or concomitant drug [29] . The proportional reporting ratio of ketoacidosis in reports where an SGLT2 inhibitor was listed was 7.9 (95%CI 7.5-8.4). The above studies listed [30] .
Although the absolute incidence of SGLT2-associated diabetic ketoacidosis in T2DM is low, several predisposing factors can be identified. These include surgery, infection and omission or dose reduction of insulin [23] .
Patients treated with SGLT2 inhibitors may present with the classical signs of diabetic ketoacidosis except that ketoacidosis often occurs with euglycaemia or mild to moderate raised blood glucose levels caused by a dissociation of hyperglycaemia and ketoacidosis [31] . Asymptomatic increases in plasma b-hydroxybutyrate without overt ketoacidosis have been reported in 12%-20% of patients taking SGLT2 inhibitors [20, 32] . It is speculated that this mild hyperketonaemia is responsible for the cardiac and renal protective effects of SGLT2 inhibitors via changing energy substrate utilisation at a mitochondrial level [33] . Currently, it is unclear at what point a patient decompensates from ketosis to ketoacidosis.
A number of mechanisms of SGLT2-induced ketoacidosis have been postulated Fig. 1 . First, SGLT2 inhibitors reduce the plasma insulin to glucagon ratio and this results in increased lipolysis and fatty acid oxidation in the liver as well as hepatic ketogenesis [7, 34] . Insulin secretion is decreased as a result of hypoglycaemia and this results in glucagon secretion [7] . In addition, alpha cells in the Islets of Langerhans express SGLT2 receptors which function as a glucose sensor [35] , and are blocked by the SGLT2 inhibitors. Blockade of this sensor mimics hypoglycaemia, thus augmenting glucagon secretion.
Second, SGLT2 inhibitors increase the renal re-absorption of ketone bodies. Sodium-glucose cotransporter type-2 inhibitors prevent the re-absorption of sodium in the proximal convoluted tubule, creating an increased concentration of sodium in the distal portions of the tubule. This results in an electrochemical gradient favouring re-absorption of negatively charged ketone bodies (acetoacetate and b-hydroxybutyrate), possibly via the sodium-monocarboxylate transporter-1 present on the apical membrane of renal tubular epithelium [36, 37] . The patient may therefore have significant ketoacidosis without ketonuria, possibly delaying diagnosis if urinary ketones are used as a screening tool. If there is a suspicion of ketoacidosis, plasma rather than urinary ketones should be directly measured, in addition to arterial pH [21] .
Third, there is a relative excess of ATP in the kidney due to reduced sodium re-absorption in the proximal tubule. This shifts the kidney away from metabolic pathways that normally produce ATP, including ammoniogenesis and ketone body oxidation, worsening the metabolic acidosis [33] .
Fourth, when insulin-dependent patients are prescribed an SGLT2 inhibitor, physicians frequently reduce the dose of insulin prescribed, sometimes excessively, resulting in insulin deficiency, lipolysis and hepatic ketogenesis [36] . This explains why the risk of euglycaemic ketoacidosis is particularly high when a SGLT2 inhibitor is prescribed to a TIDM patient, or a patient with latent autoimmune diabetes mellitus [21] .
The metabolic stress of surgery, in addition to prolonged fasting, increases the risk of SGLT2-induced ketoacidosis [21] . There are increasing reports of euglycaemic ketoacidosis in the postoperative period. The Figure 1 Sodium-glucose co-transporter type-2 (SGLT2) inhibitor-associated diabetic ketoacidosis: mechanisms.
factors that predispose SGLT2 inhibitor-associated diabetic ketosis are summarised in Table 2 .
The number of reports of SGLT2 inhibitorassociated ketosis in postoperative surgical patients is steadily increasing ( Table 3 ). The exact rate of these life-threatening adverse effects in the peri-operative period is difficult to establish as it is unrecognised and probably under-reported. Twenty-six patients have been identified where surgery was associated with ketoacidosis in patients taking SGLT2 inhibitors [23, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] . Nineteen of these were associated with canagliflozin and 20 patients had T2DM. Two patients were subsequently discovered to have T1DM based on antibodies [43, 46] . Twenty out of the 26 patients had a plasma glucose level less than 14 mmol.L -1 . Patients had undergone bariatric procedures in eight of these cases. These patients were placed on a low carbohydrate, high protein diet for 1-2 weeks pre-operatively, increasing their propensity towards a ketotic state [39, 42] . In a case report, Maraka et al. described a patient who developed two isolated episodes of ketoacidosis on days one and six following an abdominoplasty despite ceasing the SGLT2 inhibitor the day following surgery [49] . This was in the context of acute kidney injury, and is consistent with the prolonged elimination of the half-life of SGLT2 inhibitors. The SGLT2 inhibitor effect can persist for up to 10 days even in the presence of normal renal function, increasing the risk of recurrent ketoacidosis and perhaps suggesting that the pharmacodynamic effect may persist beyond five elimination half-lives [57, 58] . The time at which ketoacidosis developed postoperatively varied considerably, from one day to one month postsurgery. Thus, peri-operative physicians and surgeons need to have a high index of suspicion for symptoms and signs of ketoacidosis even beyond patient hospital discharge.
Prevention
When deciding on appropriate blood glucose management, individual patient factors, the proposed surgery and the anticipated postoperative course should be taken into account. A multidisciplinary approach involving the surgeon, anaesthetist and endocrinologist is recommended.
In the peri-operative management of patients on SGLT2 inhibitors, the most effective method of preventing diabetic ketoacidosis is to ensure that the drug is withheld during any situation where there are predisposing factors that might precipitate ketoacidosis (e.g. surgery, dehydration, alcohol intake, acute illness) [51] . Although the American Association of Clinical Endocrinologists and the American College of Endocrinology recommend stopping SGLT2 inhibitors at least 24 h before elective surgery, it may be appropriate to stop SGLT2 inhibitors approximately three days (or five half-lives) before major surgery, given that the elimination half-life of the SGLT2 inhibitors range from 11 h to 13 h and the pharmacodynamic effects may persist for several days [20] . Given that the pharmacodynamic effects of SGLT2 inhibitors may outlast their predicted half-life, some authors have recommended that they are ceased one week before elective surgery [58] .
For minor elective procedures that predispose to a ketotic state (e.g. colonoscopies requiring bowel prep and a modified diet), it is probably best if the SGLT2 inhibitor is stopped 2-3 days before the procedure. Bariatric procedures deserve special mention as patients are frequently placed on a low-carbohydrate, highprotein diet for 1-2 weeks before surgery [42] . This is to facilitate better visualisation of the operative field during laparoscopic procedures by decreasing hepatic glycogen stores and hepatic mass [39] . Under these circumstances, the SGLT2 inhibitor should be stopped two weeks before surgery. For emergency surgical cases, SGLT2 inhibitors should be stopped immediately [21] . It would be prudent to measure plasma and urinary ketones pre-operatively as volume deficits from occult gastro-intestinal losses can precipitate the ketoacidosis.
With the increasing popularity of SGLT2 inhibitors due to their extra-glycaemic effects, they are now being prescribed to patients with T1DM or latent auto-immune diabetes in adulthood (LADA). This may be inappropriate, particularly in the context of upcoming surgery, and it is probably best if the SGLT2 inhibitor is ceased altogether in the pre-admission clinic.
There are no clear guidelines regarding restarting SGLT2 inhibitors following surgery. Ideally, they should not be recommenced until the patient is clinically well, euvolaemic and tolerating a normal diet [20] . Theoretically, the postoperative period is associated with a high risk for SGLT2-associated ketoacidosis because there is reduced insulin sensitivity due to elevated catecholamines and cortisol. If the SGLT2 inhibitor is recommenced soon after surgery, the treating team must be vigilant and monitor for any symptoms of ketoacidosis (nausea, vomiting), which would mandate its immediate cessation [59] . Although not formally recommended, daily monitoring of blood b-hydroxybutyrate levels would be ideal during this high-risk period to facilitate early diagnosis. This could be done by the bedside using a blood ketone meter and a specially designed strip [60] . Bariatric patients again deserve special mention. The risk of ketoacidosis is particularly high in the postoperative period due to rapid weight loss, a low carbohydrate diet and nausea/ vomiting [61] . For these reasons it may be best if the SGLT2 inhibitor is indefinitely suspended following surgery.
Diagnosis and management
In SGLT2 inhibitor-associated diabetic ketoacidosis, patients typically present with nausea, vomiting, fatigue, abdominal pain and progressive confusion. Physical examination may detect tachycardia, Kussmaul breathing with fruity breath and dehydration. The biochemical criteria for diagnosis include the presence of ketones (b-hydroxybutyrate, aceto-acetate, acetone) in serum and urine, pH < 7.3, serum bicarbonate < 15 mmol.L -1 and an anion gap > 12 mmol.L -1 [20] .
Despite the focus in the literature on 'euglycaemic' ketoacidosis, plasma glucose levels are frequently ≥ 14 mmol.L -1 . If a patient taking a SGLT2 inhibitor is feeling unwell it would be prudent to measure serum and urine ketones. Serum b-hydroxybutyrate is the first ketone measurable at the onset of ketoacidosis, and is thus a sensitive marker, with a level over 3 mmol.L -1 considered significant [62] . It is the predominant ketone, accounting for~78% of all ketone bodies, whereas aceto-acetate accounts for 20% [60] . Urinary ketones may be misleadingly low because SGLT2 inhibitors promote tubular re-absorption of ketone bodies, and current assays using nitroprussidebased urine strips detect aceto-acetate [36, 60] . Urinary aceto-acetate becomes detectable only 2-4 h after the onset of ketonaemia [60] . Plasma potassium levels are frequently in the normal range or at the lower end, reflecting increased urinary potassium excretion in association with glycosuria [55] . This contrasts with typical diabetic ketoacidosis, where hyperkalaemia is common before treatment despite depletion of total body potassium stores. The extent of renal bicarbonate loss is greater in SGLT2-associated ketoacidosis (possibly an indirect effect on the sodium hydrogen exchanger in the proximal tubule) [4] resulting in a more severe metabolic acidosis with a mixed or even normal anion gap (AG) [55] . Many cases of ketoacidosis are severe, with a mortality rate of 1.5% [29] . Treatment consists of stopping the SGLT2 inhibitor, intravenous fluids, insulin and occasionally bicarbonate [51] . Sodium-glucose cotransporter type 2 inhibitors compound the hypovolaemia that results from diabetic ketoacidosis [22] and thus large volumes of normal saline may be required. An insulin infusion at a lower-than-usual rate of 0.05 units.kg.h -1 with an infusion of dextrose-5% and normal saline is indicated if the patient is euglycaemic [55] . Patients are significantly potassium deplete, so aggressive potassium replacement may be required via a central line. A mixed metabolic acidosis is frequently present, and the normal anion gap acidosis is slower to normalise with treatment than the increased anion gap acidosis, often lagging behind by 24-48 h [55] . Patients occasionally require tracheal intubation or non-invasive positive pressure ventilation due to respiratory failure from the metabolic acidosis or encephalopathy [44] [45] [46] . Haemodialysis is required in some cases due to refractory metabolic acidosis [44, 46] . There are reports of patients previously presumed to have type-2 diabetes who developed ketoacidosis with the use of SGLT2 inhibitors being subsequently found to have latent auto-immune diabetes of adults [22] . Therefore, depending on the clinical situation, it may be beneficial testing auto-antibodies in certain patients previously believed to have type-2 diabetes.
Conclusion
The SGLT2 inhibitors are a useful addition to the traditional oral hypoglycaemic drugs. They have been shown to be as efficacious as other oral hypoglycaemic drugs and may have protective effects on the macroand microvascular complications of diabetes. The overall safety of the SGLT2 inhibitors is good, with a lower risk of hypoglycaemia. The number of case reports of peri-operative SGLT2 inhibitor-associated ketoacidosis is steadily increasing. The exact rate at which this lifethreatening adverse effect occurs during the perioperative period during SGLT2 inhibitor therapy is difficult to establish. Its diagnosis may be delayed and it can be prevented by withholding SGLT2 inhibitors pre-operatively and when indicated.
